A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Study ID
NCT01351103

Study type
Interventional

Study phase
Phase 1

Study status
Active, not recruiting

Trial Acronym

Trial Summary

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

More informations

Trial Starting Date

Dec 01,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

185